Skip to main content
. Author manuscript; available in PMC: 2009 Dec 16.
Published in final edited form as: Mol Cell Endocrinol. 2008 Oct 4;296(1-2):1–9. doi: 10.1016/j.mce.2008.09.022

Figure 6.

Figure 6

Analysis of the E2 and tamoxifen-induced transcriptional activity of the wild type (wt) KRT13 promoter or the KRT13 promoter containing the indicated truncations or mutations. ERE positions are: ERE1 (−2129 to −2117), ERE2 (−1289 to −1277), ERE3 (−587 to −575), ERE4 (−394 to −382). (A) Schematic diagrams of the wild type and mutant constructs. (B) E2 and tamoxifen-induced transcriptional activities of the wild type and KRT13 promoter mutants were evaluated in a luciferase reporter system in MCF-7 cells. Values are the mean ± SEM from three to six separate experiments. Dunnett’s test was performed to compare each mutant with the wild type promoter for each ligand treatment. * p < 0.05, and ** p < 0.01.